@article {7726,
	title = {Paclitaxel and gemcitabine versus paclitaxel and vinorelbine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group (HeCOG)},
	journal = {Annals of Oncology},
	volume = {22},
	year = {2011},
	note = {Cited By :7Export Date: 21 February 2017},
	month = {2011},
	pages = {827 - 834},
	abstract = {Background: Paclitaxel (Taxol) and vinorelbine have shown synergism of cytotoxic effects in vitro and clinical activity in phase I and II studies. This combination was compared prospectively with the paclitaxel/gemcitabine regimen in non-operable non-small-cell lung cancer. Patients and methods: Chemotherapy-naive patients, stage IIIbwet and IV with performance status (0-1), were randomized to receive paclitaxel 200 mg/m2 on day 1 plus gemcitabine 1 gm/m2 (group A) on days 1 and 8 every 3 weeks or paclitaxel 80 mg/m2 plus vinorelbine 22.5 mg/m2 (group B) on days 1, 8 and 15 every 4 weeks. Results: A total of 398 out of 415 patients were eligible for analysis on intent-to-treat basis (group A: 196, group B: 202). Progression-free survival (PFS) was 5.0 months [95\% confidence interval (CI) 4.3-5.6] and 4.4 months (95\% CI 3.7-5.2) for groups A and B respectively (P = 0.365). Median survival was 11.1 months (95\% CI 9.2-13.0) and 8.6 months (95\% CI 7.0-10.2) for groups A and B respectively (P = 0.147). Grade 3/4 neutropenia and leukopenia were worse in group B (P \&lt; 0.001, in both cases). Febrile neutropenia and severe infections were more prominent (P \&lt; 0.001, P = 0.029 respectively) in group B. Conclusion: Although response rate, PFS and survival were non-different in both groups, toxicity was significantly worse in group B and therefore further investigation of P-Vin is of no value. {\textcopyright} The Author 2010. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.},
	keywords = {Chemotherapy, Gemcitabine, NSCLC, Paclitaxel, Vinorelbine},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-79953302404\&doi=10.1093\%2fannonc\%2fmdq445\&partnerID=40\&md5=3bdcb37d9f5f893a96298b9cc4de3df2},
	author = {Kosmidis, P.A. and Fountzilas, G. and Eleftheraki, A.G. and Kalofonos, H.P. and Pentheroudakis, G. and Skarlos, D. and Dimopoulos, M.A. and Bafaloukos, D. and Pectasides, D. and Samantas, E. and Boukovinas, J. and Lambaki, S. and Katirtzoglou, N. and Bakogiannis, C. and Syrigos, K.N.}
}
